• PNS274 CRITICALLY APPRAISING SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS: WHAT, WHY AND HOW? AN EXPLORATORY STUDY USING AN IRISH NATIONAL CLINICAL GUIDELINE

    Nov 1, 2019, 00:00

  • PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • Cancer - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMU6 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 5% LIDOCAINE-MEDICATED PLASTER VS. PREGABALIN

    Nov 1, 2019, 00:00

  • PRO99 MULTI-CRITERIA DECISION ANALYSIS (MCDA) OF ELTROMBOPAG OLAMINE IN THE TREATMENT OF PATIENTS WITH REFRACTORY SEVERE APLASTIC ANEMIA UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: A HEALTH TECHNOLOGY ASSESSMENT (HTA) ALTERNATIVE MODEL

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PCN36 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS FOR TREATMENT OF MODERATE TO SEVERE PSORIASIS PATIENTS OVER 1 YEAR IN MOROCCO

    Nov 1, 2019, 00:00

  • PDB121 THE FINANCIAL IMPACT OF FEBUXOSTAT REIMBURSEMENT TO THE TAIWAN NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PBI93 CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PCN117 COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+ EARLY BREAST CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • PGI55 QUALITY OF LIFE AND PATIENT PREFERENCE AMONG DANISH PATIENTS WITH ULCERATIVE COLLITIS - RESULTS FROM A SURVEY STUDY

    Nov 1, 2019, 00:00

  • PNS200 ANALYSIS OF HOSPITAL USE OF SURGERY WARDS TO OPTIMIZE HOSPITAL INFRASTRUCTURE PLANNING

    Nov 1, 2019, 00:00

  • Alternative Medicine Public Health

    Nov 1, 2019, 00:00

  • PIN4 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN OTHERWISE HEALTHY AND HIGH-RISK ADULTS

    Nov 1, 2019, 00:00

  • PGI33 THE COST-EFFECTIVENESS OF FAECAL MICROBIOTA TRANSPLANTATION VS. ANTIBIOTICS FOR PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PRS37 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED CHRONIC COUGH: 2018 CHRONIC COUGH SURVEY

    Nov 1, 2019, 00:00

  • PNS33 PUBLICATION TREND AND CITATION ANALYSIS OF ARTICLES PUBLISHED IN "VALUE IN HEALTH” BETWEEN 1998-2019

    Nov 1, 2019, 00:00

  • PRS10 UNDERSTANDING EMPHYSEMA BURDEN AND TREATMENT PATTERNS IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PBI62 REAL-WORLD EVIDENCE ON THERAPEUTIC DRUG MONITORING OF TNF-INHIBITORS IN INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PMD38 THE CLINICAL AND ECONOMIC ANALYSES OF VIDEO ASSISTED THORACOSCOPIC SURGERY FOR LOBECTOMY: EXPERIENCE FROM A TOP ACADEMIC MEDICAL CENTER IN CHINA

    Nov 1, 2019, 00:00

  • PNS380 BREAST CANCER PATIENT PERSPECTIVES ON IMPORTANT SYMPTOM INFORMATION

    Nov 1, 2019, 00:00

  • PRO39 CONCEPTUAL FRAMEWORK FOR EVALUATING THE COST-EFFECTIVENESS OF A GENE THERAPY FOR HAEMOPHILIA B

    Nov 1, 2019, 00:00

  • PCN27 INTRAPATIENT COMPARISONS IN SINGLE ARM TRIALS FOR TUMOR AGNOSTIC INDICATIONS WITH APPLICATION TO ENTRECTINIB

    Nov 1, 2019, 00:00

  • PNS230 CALL FOR EFFECTIVE GUIDANCE: ASSESSMENT OF PHARMACOTHERAPEUTIC GUIDELINES IMPLEMENTATION

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN472 PATIENT REPORTED HEALTH STATE UTILITIES IN CUTANEOUS T-CELL LYMPHOMA (CTCL) - AN ANALYSIS OF EQ-5D AND SKINDEX-29 DATA COLLECTED FROM THE ALCANZA TRIAL

    Nov 1, 2019, 00:00

  • PDG44 JOINT HTA AND DRUG PRICING COLLABORATIONS IN EU: BY WHOM AND WHEN TO BE PURSUED?

    Nov 1, 2019, 00:00

  • PBI56 SUSTAINABLE BIOSIMILAR PROCUREMENT IN EUROPE: A REVIEW OF CURRENT POLICIES AND THEIR POTENTIAL IMPACT

    Nov 1, 2019, 00:00

  • PCV93 RESOURCE USE AND COSTS OF ACUTE CORONARY SYNDROME: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS295 BEST WORST SCALING: FOR GOOD OR FOR BAD BUT NOT FOR BOTH

    Nov 1, 2019, 00:00

  • PSY53 PATIENT PREFERENCES IN THE TREATMENT OF HEMOPHILIA: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN145 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB IN ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION IN FRANCE

    Nov 1, 2019, 00:00

  • PPM5 COSTS OF IN-HOUSE MUTATIONAL-TESTING AND IMPLICATIONS FOR ECONOMIC EVALUATION: A CASE EXAMPLE OF NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PRS56 MACHINE LEARNING PREDICTION OF ASTHMA NON-SCHEDULED VISITS IN THE BRAZILIAN PRIVATE HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PNS14 TOWARDS CONSISTENCY AND COHERENCE IN UNDERSTANDING THE ECONOMIC IMPACT OF DISEASE

    Nov 1, 2019, 00:00

  • PCN223 A BUDGET IMPACT ANALYSIS OF A COMMUNITY-BASED SUPPORT CENTRE FOR CANCER PATIENTS AND SURVIVORS

    Nov 1, 2019, 00:00

  • PSY28 EPIDEMIOLOGY OF ATOPIC DERMATITIS IN SCHOOLCHILDREN AND ADOLESCENTS IN ITALY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • PSY34 TWO SIDES OF THE SAME COIN? A DUAL MULTIPLE CRITERIA DECISION ANALYSIS OF NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS FROM PHYSICIANS' AND PATIENTS' PERSPECTIVES IN GREECE

    Nov 1, 2019, 00:00

  • PCV19 COMPARATIVE RISK OF HEART FAILURE HOSPITALIZATIONS ASSOCIATED WITH DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • PMU71 EFFECTIVE IMPLEMENTATION OF BIOSIMILAR MEDICINE AT PATENT EXPIRATION TO ACHIEVE OPTIMAL FINANCIAL GAIN: BEST PRACTICE MODEL WITH ADALIMUMAB AS CASE

    Nov 1, 2019, 00:00

  • PCN219 WHAT IS WORTH KNOWING AT EARLY DEVELOPMENT? VALUE OF INFORMATION ANALYSIS USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A CASE STUDY

    Nov 1, 2019, 00:00

  • PMU25 USING MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) TO CREATE A PRIORITY LIST OF CHRONIC NON-COMMUNICABLE DISEASES (NCDS) TO GUIDE HEALTH RESEARCH SPENDING

    Nov 1, 2019, 00:00

  • PIH58 THE EFFECT OF LONG-LASTING INTAKE OF MG AND B12ON THE MOTHER AND THE INTRA-UTERINE DEVELOPMENT OF THE FOETUS AS WELL AS THE OUTCOME OF DELIVERY

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PNS50 ECONOMIC IMPACT OF THE DEVELOPMENT OF OUTPATIENT SURGERY IN FRANCE

    Nov 1, 2019, 00:00

  • PRS43 SOCIAL BURDEN AND MEDICAL COST OF COPD IN KOREA

    Nov 1, 2019, 00:00

  • PCV126 PATIENT PREFERENCES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Drugs Public Health

    Nov 1, 2019, 00:00

  • PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PNS24 NORDIC COLLABORATIONS ON PROCUREMENT AND HEALTH TECHNOLOGY ASSESSMENT: CONCEPTS, COMPONENTS, AND OUTLOOK

    Nov 1, 2019, 00:00

  • PMU134 PATIENT CENTRICITY? PATIENT NOISE IN SOCIAL MEDIA AND SUPPORT PROGRAMS IN THE GERMAN HEALTHCARE ENVIRONMENT

    Nov 1, 2019, 00:00

  • PNS255 USING PEST ANALYSIS TO CREATE AN HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PCV111 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN CARDIOLOGY AND DIABETOLOGY

    Nov 1, 2019, 00:00

  • PMU74 FIRST 27 MONTHS OF CONDITIONAL REIMBURSEMENT IN FINLAND

    Nov 1, 2019, 00:00

  • PCV34 RIVAROXABAN PLUS ASPIRIN FOR THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE

    Nov 1, 2019, 00:00

  • PDB120 COSTS AND RESOURCE USE ASSOCIATED WITH SEVERE HYPOGLYCEMIC EVENTS IN PATIENTS WITH DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • PND58 AN ECONOMIC EVALUATION ATTACHED TO A SINGLE-CENTRE, PARALLEL GROUP, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF AN THREE DAY INTENSIVE SOCIAL COGNITIVE TREATMENT (CAN DO TREATMENT) IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSI ...

    Nov 1, 2019, 00:00

  • PGI49 CHANGES IN HEALTH RELATED QUALITY OF LIFE IN CROHN'S DISEASE PATIENTS FOLLOWING MINDFULNESS-BASED COGNITIVE INTERVENTION: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2019, 00:00

  • PIN98 NATIONAL BURDEN OF SEPSIS IN INDONESIA: AN ANALYSIS BASED ON FOCAL INFECTIONS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PRO47 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • Injury Trauma - Organizational Practices

    Nov 1, 2019, 00:00

  • PMH56 THE IMPACT OF PHYSICAL AND MENTAL STRESS ON THE PRODUCTIVITY LOSS IN JAPANESE WORKPLACE

    Nov 1, 2019, 00:00

  • PMS34 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE WRIST AND HAND IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

    Nov 1, 2019, 00:00

  • PDB37 A SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF COST-EFFECTIVENESS ANALYSIS OF INSULIN PUMPS COMPARED WITH MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS

    Nov 1, 2019, 00:00

  • PCV147 DATA QUALITY EVALUATION OF 5 MUNICIPAL AND PROVINCIAL CLAIMS DATABASES OF FUJIAN PROVINCE IN CHINA

    Nov 1, 2019, 00:00

  • PDG86 ECONOMIC EVALUATION FOR PRICING AND REIMBURSEMENT OF NEW DRUGS IN SPAIN: FABLE OR DESIDERATUM?

    Nov 1, 2019, 00:00

  • PMH70 DIRECT HEALTHCARE COSTS FOR THE MANAGEMENT OF PATIENTS WITH OPIOID USE DISORDER TREATED WITH METHADONE AND BUPRENORPHINE/NALOXONE IN REAL-WORLD SETTING IN SPAIN. COSTEDOPIA STUDY

    Nov 1, 2019, 00:00

  • PIN92 DO INTERNATIONAL MIGRANTS FACE HIGHER BACTERIAL DRUG RESISTANCE COMPARED TO NATIVES? A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN56 EXCESS HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH PERTUSSIS INFECTION IN OLDER ADULTS

    Nov 1, 2019, 00:00

  • PMH29 ESTIMATING A PREFERENCE-BASE INDEX FROM THE RECOVERING QUALITY OF LIFE MEASURE FOR ECONOMIC EVALUATION IN THE AREA OF MENTAL HEALTH: VALUATION OF REQOL-UI

    Nov 1, 2019, 00:00

  • PCV123 DETERMINANTS OF POOR QUALITY OF LIFE AND HIGH HEALTH CARE RESOURCE CONSUMPTION IN HEART FAILURE PATIENTS IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PMU95 IS THERE REGIONAL VARIATION IN WORSE AND SLOWER COST/QALY HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING TWO VS. ONE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

    Nov 1, 2019, 00:00

  • PNS85 SELF-MEDICATION PRACTICES AMONG PATIENTS IN SAUDI ARABIA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • MT4 COST ANALYSIS OF INTEGRATED VERSUS CONVENTIONAL OPERATING ROOMS

    Nov 1, 2019, 00:00

  • PCN93 HEALTH RESOURCE UTILIZATION IN ADVANCED OVARIAN AND ENDOMETRIAL CANCER IN A UNITED STATES INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PNS418 WHEN THE COMPARATOR HAS A CONFIDENTIAL PRICE - A REVIEW OF RECENT CASES IN SWEDEN

    Nov 1, 2019, 00:00

  • PRO12 HOW DOES RISDIPLAM COMPARE IN INFANTILE ONSET SPINAL MUSCOLAR ATROPHY (SMA)? PRELIMINARY INDIRECT TREATMENT COMPARISONS BASED ON FIREFISH PART 1 DATA

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

    Nov 1, 2019, 00:00

  • PBI25 COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL

    Nov 1, 2019, 00:00

  • PIN117 THE COST OF INFLUENZA RELATED HOSPITALIZATIONS IN ELDERLY IN TURKEY

    Nov 1, 2019, 00:00

  • PBI71 EXPLORING UNCERTAINTIES AND SOLUTIONS ALLOWING PATIENT ACCESS TO CAR T-CELL THERAPIES: LEARNING TODAY HOW TO IMPROVE TOMORROW

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE

    Nov 1, 2019, 00:00

  • PCV127 PATIENT PREFERENCES REGARDING ORAL ANTICOAGULANTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT IN SPANISH PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN-K ANTAGONISTS

    Nov 1, 2019, 00:00

  • PNS199 BARRIERS TO THE USE OF HEALTH SERVICES AMONG THE ELDERLY POPULATION OF A RURAL REGIONAL UNITY IN GREECE: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PBI19 GENE THERAPIES: HOW WILL INDICATION-BASED PRICING AFFECT PATIENT ACCESS AND COST-CONTAINMENT MECHANISMS FOR PAYERS?

    Nov 1, 2019, 00:00

  • PNS168 REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION

    Nov 1, 2019, 00:00

  • PMU122 UPDATING DISABILITY WEIGHTS FOR MEASUREMENT OF HEALTHY LIFE EXPECTANCY AND DISABILITY-ADJUSTED LIFE YEAR IN KOREA

    Nov 1, 2019, 00:00

  • PRS27 THE USE OF ECONOMICAL TRADITIONAL HERBAL MEDICINAL PLANTS AMONG DIFFERENT COMMUNITIES OF BALOCHISTAN AGAINST ASTHMA

    Nov 1, 2019, 00:00

  • Personalized Regulatory

    Nov 1, 2019, 00:00

  • PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN379 HTA ASSESSMENTS OF METASTATIC UROTHELIAL CARCINOMA TREATMENT IN EU COUNTRIES

    Nov 1, 2019, 00:00

  • PCN304 REIMBURSEMENT AND PAYER MANAGEMENT OF IMMUNE CHECKPOINT INHIBITORS IN KEY EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • PIT8 ESTIMATION OF THE ECONOMIC BURDEN ASSOCIATED WITH 90-DAY COMPLICATIONS FOLLOWING INTERTROCHANTERIC HIP FRACTURE

    Nov 1, 2019, 00:00

  • PSY43 HEALTH STATE UTILITIES ASSOCIATED WITH SICKLE CELL DISEASE AND ITS TREATMENT: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN349 VALUE OF INFORMATION ANALYSIS GUIDING THE REIMBURSEMENT DECISION OF OLAPARIB FOR METASTATIC BREAST CANCER

    Nov 1, 2019, 00:00

  • PSY44 ECONOMIC BURDEN OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) TO PATIENTS: COMPARATIVE STUDY

    Nov 1, 2019, 00:00

  • PSS5 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN FRANCE

    Nov 1, 2019, 00:00

  • PNS98 A QUALITATIVE EXPLORATION OF KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS ABOUT PHARMACOVIGIILANCE ACTIVITIES IN TERTIARY CARE HOSPITALS OF LAHORE, PAKISTAN

    Nov 1, 2019, 00:00

  • New Frontiers in Oncology Cost Studies

    Nov 1, 2019, 00:00

  • PMU138 EXPLORATIVE SCOPING REVIEW AND BIBLIOMETRIC ANALYSIS OF BIG DATA APPLICATIONS FOR MEDICATION ADHERENCE

    Nov 1, 2019, 00:00

  • PIH21 COST-EFFECTIVENESS OF ORAL CARE IN INSTITUTIONALIZED OLDER PEOPLE

    Nov 1, 2019, 00:00

  • PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) A ...

    Nov 1, 2019, 00:00

  • PSY11 ECONOMIC BURDEN OF PSORIASIS IN GREECE: RESULTS OF A MULTICENTRE, PROSPECTIVE, EPIDEMIOLOGICAL STUDY

    Nov 1, 2019, 00:00

  • PMU143 PATIENT CENTRICITY IN PATIENT PREFERENCE STUDIES: INTERVIEWS WITH PATIENTS

    Nov 1, 2019, 00:00

  • PMD4 SECONDARY CATARACT PROCEDURES DUE TO POSTERIOR CAPSULAR OPACIFICATION IN THE CZECH REPUBLIC: AN ANALYSIS OF HEALTH INSURANCE DATA

    Nov 1, 2019, 00:00

  • PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN475 PERCEPTIONS AND EXPERIENCES OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: A UK CASE STUDY

    Nov 1, 2019, 00:00

  • PMD20 COST EFFECTIVENESS ANALYSIS OF IMPLANTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDG56 BIOSIMILAR MARKET DYNAMICS IN KOREA

    Nov 1, 2019, 00:00

  • Infectious Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PSU33 REDUCTION IN DISCECTOMY TIME AND INSTRUMENT PASSES WITH THE CONCORDE® CLEAR MIS DISCECTOMY DEVICE FOR TRANSFORAMINAL LUMBAR INTERBODY FUSION DISCECTOMY

    Nov 1, 2019, 00:00

  • PND124 A REAL-WORLD DATA STUDY TO ANALYSE THE PHARMACOLOGICAL TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN SPAIN

    Nov 1, 2019, 00:00

  • PBI5 IS ICER INCREASING INFLUENCE IN THE USA OVER TIME?

    Nov 1, 2019, 00:00

  • PNS71 ROLE OF INFORMATION IN DEMAND FOR HEALTH SERVICES: AN INSTRUMENTAL VARIABLE APPROACH

    Nov 1, 2019, 00:00

  • PNS257 PERCEPTIONS ON THE PHARMACISTS' ROLE IN HTA DECISION MAKING IN GREECE

    Nov 1, 2019, 00:00

  • PIN47 FACING LIMITED ALTERNATIVES TO TREAT MULTI-DRUG RESISTANT BACTERIA IN THE FIELD OF NOSOCOMIAL PNEUMONIA

    Nov 1, 2019, 00:00

  • PCV106 ANTIHYPERTENSIVE AGENT UTILIZATION AMONG PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • Infectious Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDB90 IS IT POSSIBLE TO AUTOMATE A SYSTEMATIC LITERATURE REVIEW?

    Nov 1, 2019, 00:00

  • PMU92 THE DANISH MEDICINE COUNCIL'S PROCESS OF ASSESSING NEW HOSPITAL MEDICINES: AN ANALYSIS OF DECISIONS 2017-2019

    Nov 1, 2019, 00:00

  • PCN2 REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE: PRELIMINARY RESULTS FROM A REGISTRY

    Nov 1, 2019, 00:00

  • PNS314 RELAXING THE MEMORYLESS PROPERTY WITHIN A MARKOV MODEL

    Nov 1, 2019, 00:00

  • PNS103 PHARMACY RESEARCH BASIC KNOWLEDGE IN THE KINDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • Expanding Horizon of Outcome Studies in Oncology

    Nov 1, 2019, 00:00

  • PCV11 BURDEN OF HOSPITALISATIONS/READMISSIONS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION – A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG80 INFLUENCING FACTORS FOR A RENEWED BENEFIT ASSESSMENT IN THE GERMAN HTA PROCESS - A COMPARATIVE OVERVIEW OF §13 AND §14 IN CHAPTER 5 OF THE G-BA RULES OF PROCEDURE

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMU15 ECONOMIC IMPACT OF PREVENAR 13 VACCINATION AGAINST PNEUMOCOCCAL PNEUMONIA HOSPITALIZATIONS IN DANES 65+ WITH A CHRONIC DISEASE - A MODELLED ANALYSIS

    Nov 1, 2019, 00:00

  • HT4 INCLUSION OF PATIENT INPUT IN VALUE AND HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2019, 00:00

  • PRO79 EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

    Nov 1, 2019, 00:00

  • Individual's Health - Clinical Outcomes

    Nov 1, 2019, 00:00

  • CV2 NATIONAL SAVINGS FROM TELEHEALTH CARE IN HEART FAILURE RESULTS FROM THE DANISH TELECARE NORTH TRIAL

    Nov 1, 2019, 00:00

  • PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PND27 BUDGET IMPACT MODEL (BIM) FOR THE EQUISTASI® DEVICE

    Nov 1, 2019, 00:00

  • PIN25 EXPLORATORY ANALYSIS OF THE ECONOMICALLY JUSTIFIABLE PRICE OF AN RSV VACCINE FOR THE ELDERLY IN THE NETHERLANDS AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PRS61 A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PCN367 STOOL DNA TESTING FOR EARLY DETECTION OF COLORECTAL CANCER

    Nov 1, 2019, 00:00

  • PRO66 INCIDENCE AND PREVALENCE OF T-CELL LYMPHOMA IN THE EMA MEMBER STATES: METHODOLOGY FOR ESTIMATION IN RARE MALIGNANCIES OF CTCL AND PTCL

    Nov 1, 2019, 00:00

  • PCN105 COST-UTILITY OF NIVOLUMAB FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER (R/M SCCHN) IN FRANCE

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PMU78 APPLICATION OF MACHINE LEARNING TECHNIQUES IN EARLY DISEASE DETECTION: A REVIEW

    Nov 1, 2019, 00:00

  • PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PIN66 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-AVIBACTAM VERSUS COLISTIN-MEROPENEM IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN COLOMBIA

    Nov 1, 2019, 00:00

  • PCN252 RISK OF LUNG CANCER AMONG SMOKING WOMEN TREATED WITH RADIOTHERAPY FOR PRIMARY BREAST CANCER: FRENCH PROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • TP2 TREATMENT PATTERNS IN SPINAL MUSCULAR ATROPHY: INTERVIEWS WITH HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN427 ASSESSING THE PERFORMANCE OF PARAMETRIC SURVIVAL MODELS USING REAL WORLD EVIDENCE IN CML, LUNG AND PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PCV24 REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMH59 VALIDATION OF A SCREENING INSTRUMENT OF ADDICTION TO FAST FOOD IN SPANISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • Medical Devices - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY

    Nov 1, 2019, 00:00

  • Drugs Generics - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS

    Nov 1, 2019, 00:00

  • PCV76 COMTEMPORARY HEART FAILURE TREATMENT PATTERN AND COST IN CHINESE PATIENTS POPULATIONS

    Nov 1, 2019, 00:00

  • PRO101 ORPHAN DRUG REIMBURSEMENT IN ENGLAND AND IMPLICATIONS FOR PATIENT ACCESS

    Nov 1, 2019, 00:00

  • PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

    Nov 1, 2019, 00:00

  • PBI51 TRENDS IN THE THERAPEUTIC BIOLOGICS ATHORIZED BY FDA, EMA AND THE SAUDI FDA IN THE PERIOD 1996-2018

    Nov 1, 2019, 00:00

  • PRO104 DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Infectious Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN511 ASSOCIATED FACTORS AFFECTING RECURRENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA

    Nov 1, 2019, 00:00

  • ON8 CHEMOTHERAPY INDUCED NAUSEA VOMITING: VALIDATION OF RISK SCORING ALGORITHM IN PATIENTS WITH GYNECOLOGICAL AND GASTROINTESTINAL CANCERS

    Nov 1, 2019, 00:00

  • PDB67 MAIN PREDICTORS OF DIABETES MELLITUS TYPE 2 (DM2T) IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN216 THE SOCIETAL IMPACT OF LENALIDOMIDE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY

    Nov 1, 2019, 00:00

  • PDB89 COST-EFFECTIVENES ANALYSIS OF USING PEGVISOMANT FOR TREATMENT OF ACROMEGALY IN RUSSIA

    Nov 1, 2019, 00:00

  • NO Specific Disease - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV43 BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER FOR THE TREATMENT OF LARGE VESSEL STROKES: A U.S. PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN231 COST-EFFECTIVENESS OF REGORAFENIB FOR METASTATIC COLORECTAL CANCER IN THE CONTEXT OF THE HEALTHCARE SYSTEM OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Medical Technologies

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PRO147 MAPPING PROQOLID TO RARE DISEASES: A ON-GOING COLLABORATION BETWEEN MAPI RESEARCH TRUST AND ORPHANET

    Nov 1, 2019, 00:00

  • PRS28 ECONOMIC AND ENVIRONMENTAL IMPACTS OF A VOLUNTARY SHIFT IN INHALER PRESCRIBING IN THE ENGLISH NHS

    Nov 1, 2019, 00:00

  • PNS149 STATUS OF COMPASSIONATE USE PROGRAMMES (CUP) IN THE EU-5 (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)

    Nov 1, 2019, 00:00

  • PRS13 COST-UTILITY ANALYSIS OF MACITENTAN IN COMPARISON WITH BOSENTAN IN PULMONARY ATRIAL HYPERTENSION (PAH)

    Nov 1, 2019, 00:00

  • PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN198 FRACTIONAL POLYNOMIAL MODELS FOR NETWORK META-ANALYSIS OF SURVIVAL DATA IN ECONOMIC EVALUATIONS: A CASE-STUDY ON THE COST-EFFECTIVENESS OF FULVESTRANT IN PREVIOUSLY-TREATED POSTMENOPAUSAL, OESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST ...

    Nov 1, 2019, 00:00

  • PMD52 MEDICAL DEVICES AND SUSTAINABILITY: CLAIMS AND EVIDENCE IN NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Nov 1, 2019, 00:00

  • PNS164 PHARMACOECONOMIC ASSESSMENT AND DRUG COSTS OF TREATMENTS FOR CANCER AND RARE DISEASES IN IRELAND

    Nov 1, 2019, 00:00

  • PCN199 COST-UTILITY ANALYSIS OF THE BI-, QUADRI-, AND NONA-VALENT HPV-VACCINE: A DECISION ANALYTIC MODEL

    Nov 1, 2019, 00:00

  • Patient Reported Outcomes Quality of Life Studies

    Nov 1, 2019, 00:00

  • PCN59 CHARACTERISING ERRORS INCURRED BY MODEL SELECTION BASED ON AIC FOR EXTRAPOLATION OF SURVIVAL IN HEALTH TECHNOLOGY ASSESSMENT - A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2019, 00:00

  • PNS338 DEVELOPMENT, VALIDATION AND ASSESSMENT OF RELIABILITY OF DDQ-KAP 16 QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PCN534 BARRIERS AND FACILITATORS TO IMPLEMENTING ELECTRONIC PATIENT-REPORTED OUTCOMES (PROS) IN CANCER CLINICAL TRIALS: INTERVIEW RESULTS FROM CLINICAL RESEARCH STAFF AND PATIENTS

    Nov 1, 2019, 00:00

  • PRO139 A PATIENT-CENTRIC APPROACH TO COST OF ILLNESS RESEARCH: A CASE EXAMPLE OF PATIENT ENGAGEMENT TO IDENTIFY THE HIDDEN COSTS ASSOCIATED WITH BLINDNESS DUE TO INHERITED RETINAL DYSTROPHIES

    Nov 1, 2019, 00:00

  • PRS19 BURDEN OF DISEASE OF FIBROSING INTERSTITIAL LUNG DISEASES IN EUROPE: THE BUILDUP PROJECT

    Nov 1, 2019, 00:00

  • PMS73 DEPRESCRIBING OF ANALGESICS AND REPLACEMENT WITH PHYSIOTHERAPY IN THE DEPARTMENT OF ORTHOPEDICS FOR KNEE OSTEOARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • CL3 THE ASSOCIATION BETWEEN TREATMENT INTENSITY AND ADHERENCE TO LIPID-LOWERING THERAPIES AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PRIMARY AND SECONDARY CARE: A SWEDISH REGISTRY-BASED STUDY

    Nov 1, 2019, 00:00

  • PNS77 CHALLENGES OF STUDIES ON ECONOMIC EVALUATION IN CHILD HEALTH IN CHINA-BASED ON A REVIEW OF PUBLISHED LITERATURE

    Nov 1, 2019, 00:00

  • PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES

    Nov 1, 2019, 00:00

  • PMS6 QUALITY OF LIFE OF PATIENTS UNDERWENT IMPLANTATION OF KNEE ENDOPROSTHESIS

    Nov 1, 2019, 00:00

  • PMD57 TOTAL HOSPITAL COSTS AND READMISSION RATE OF PATIENT-SPECIFIC CUTTING GUIDE IN TOTAL KNEE ARTHROPLASTY (TKA) PATIENTS

    Nov 1, 2019, 00:00

  • PMU147 PUBLICATION PATTERNS OF HEALTH ECONOMIC OUTCOME DATA OVER 2 DECADES: AN INCREASE IN PEER-REVIEWED HEOR PUBLICATIONS ACROSS INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PDG100 PARENTERAL PREPARATIONS STEWARDSHIP IN A TEACHING HOSPITAL IN NIGERIA

    Nov 1, 2019, 00:00

  • PCN129 COST STRUCTURE ANALYSIS: DRUG THERAPY OF PATIENTS WITH STOMACH CANCER IN MOSCOW. ANALYSIS OF PATIENT DETECTION

    Nov 1, 2019, 00:00

  • PSY4 THE USE OF EQ-5D VISUAL ANALOG SCALE (EQ-VAS) IN DISEASES AREAS WHERE EQ-5D IS INSENSITIVE TO CHANGES IN THE DISEASE STATUS: THE CASE OF LIPODYSTROPHY

    Nov 1, 2019, 00:00

  • PNS354 MARKET ACCESS AS DEFINED BY MARKET ACCESS (MA), HEALTH ECONOMICS, AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS

    Nov 1, 2019, 00:00

  • PNS41 A PRAGMATIC METHOD FOR COSTING IMPLEMENTATION STRATEGIES USING THE TIME-DRIVEN ACITVITY-BASED COSTING

    Nov 1, 2019, 00:00

  • PNS184 THE VALUE OF BLOOD IN SUB-SAHARAN AFRICA

    Nov 1, 2019, 00:00

  • PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)

    Nov 1, 2019, 00:00

  • PMU17 COSTS ASSOCIATED WITH THE MANAGEMENT OF CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA IN ADULT PATIENTS UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • PGI5 COLECTOMY FOR ULCERATIVE COLITIS IN THE UK: A REVIEW OF INCIDENCE AND COMPLICATIONS

    Nov 1, 2019, 00:00

  • PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS

    Nov 1, 2019, 00:00

  • PCV10 EFFECT OF LOW PRIME VOLUME ON HEMATOCRIT IN CORONARY ARTERY BYPASS SURGERY

    Nov 1, 2019, 00:00

  • VALUE Assessment of Medical Technology

    Nov 1, 2019, 00:00

  • PND111 DESIGN OF THE INDIVIDUALISED MEMORY DEPENDENT QUALITY OF LIFE (MEMORYDQOL) AND THE MEMORY TREATMENT SATISFACTION QUESTIONNAIRE (MEMORYTSQ) FOR PEOPLE WITH DEMENTIA USING EXISTING DQOL AND TSQ TEMPLATES AND ITEM LIBRARIES

    Nov 1, 2019, 00:00

  • PCV145 ASSOCIATION BETWEEN NICORANDIL AND GASTROINTESTINAL ULCERS: A POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PDB127 BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS118 DEVELOPMENT AND POTENTIALS OF HEALTH TECHNOLOGY ASSESSMENT SYSTEM IN KAZAKHSTAN.

    Nov 1, 2019, 00:00

  • PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

    Nov 1, 2019, 00:00

  • PMS47 SIZING THE PATIENT POTENTIAL FOR DISEASE MODIFYING OSTEOARTHRITIS THERAPIES IN USA AND EU MARKETS

    Nov 1, 2019, 00:00

  • PCN167 SELF-REPORTED OUT-OF-POCKET EXPENSES, INCOME LOSS, AND INFORMAL CARE INCURRED BY CANCER PATIENTS IN SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PMD56 NETWORK META-ANALYSIS OF THE USE OF ISTENT® INJECT MICROINVASIVE SURGERY IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS

    Nov 1, 2019, 00:00

  • PGI19 COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE

    Nov 1, 2019, 00:00

  • Adherence, Persistence and Compliance Studies

    Nov 1, 2019, 00:00

  • AI3 DEVELOPMENT OF A DECISION-AID FOR PATIENTS WITH DEPRESSION CONSIDERING TREATMENT OPTIONS: PREDICTION OF TREATMENT RESPONSE USING A DATA-DRIVEN APPROACH

    Nov 1, 2019, 00:00

  • PRO64 MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION

    Nov 1, 2019, 00:00

  • PND14 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WHO FAILED TO VALPROIC ACID TREATMENT

    Nov 1, 2019, 00:00

  • PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PND21 PROJECT HERCULES: A NEW PARADIGM FOR PATIENT-CENTRED COLLABORATION IN HTA

    Nov 1, 2019, 00:00

  • PNS221 ANALYSIS OF HTA DOSSIERS SUBMISSION AND RECOMMENDATION REPORTS FOR DRUG PROCUREMENT AND REIMBURSMENT IN UKRAINE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES

    Nov 1, 2019, 00:00

  • PND132 CLAIMS DATABASE ANALYSIS OF HEADACHE AND MIGRAINE IN SPAIN 2011-2016: PATIENT PROFILE, HEALTHCARE MANAGEMENT AND DIRECT MEDICAL COSTS

    Nov 1, 2019, 00:00

  • PCN510 HEALTHCARE RESOURCE UTILISATION (HCRU) ASSOCIATED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLISATION (TACE) TREATMENT IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS IN EUROPE

    Nov 1, 2019, 00:00

  • PCN313 REAL-WORLD DATA ON THE USE OF ANTINEOPLASTIC PHARMACOTHERAPY REGIMENS AMONG PATIENTS WITH SKIN MELANOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PIN76 BUDGET IMPACT OF CEFTAZIDIME AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTION AND HOSPITAL-ACQUIRED PNEUMONIA IN SINGAPORE

    Nov 1, 2019, 00:00

  • PNS387 MULTI-CRITERIA DECISIONAL ANALYSIS ON NON-EMERGENCY MEDICAL TRANSPORT IN HONG KONG CONTEXT

    Nov 1, 2019, 00:00

  • PRO141 ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS

    Nov 1, 2019, 00:00

  • PNS215 IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES

    Nov 1, 2019, 00:00

  • PIN6 EVALUATION OF DIRECT-ACTING ANTIVIRALS RETREATMENT IN NON-SUSTAINED VIROLOGICAL RESPONDERS

    Nov 1, 2019, 00:00

  • PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)

    Nov 1, 2019, 00:00

  • PRO63 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM CANADA AND THE US

    Nov 1, 2019, 00:00

  • PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PND60 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH INCIDENT MIGRAINE INITIATING TREATMENT - A COHORT STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK

    Nov 1, 2019, 00:00

  • PNS211 SWOT ANALYSIS FOR CREATION OF HTA ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN159 COST-UTILITY ANALYSIS OF TRIFLURIDINE/TIPIRACIL FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN

    Nov 1, 2019, 00:00

  • PGI24 IBD INTEGRATED MODEL OF CARE LEADS TO COST SAVINGS: A BUDGET IMPACT MODEL FOR A RUSSIAN REGION

    Nov 1, 2019, 00:00

  • PSY2 SYSTEMIC LUPUS ERYTHEMATOSUS: A TARGETED LITERATURE REVIEW OF ECONOMIC BURDEN WORLDWIDE

    Nov 1, 2019, 00:00

  • CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PMU128 MY DAUGHTER LOVES THE NEW PENS!: QUANTIFYING THE PATIENT EXPERIENCE WITH MACHINE READING AND APPLIED SEMANTIC COMPUTING

    Nov 1, 2019, 00:00

  • PIN65 COST-EFFECTIVENESS ANALYSIS ON ELDERLY PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS: CHALLENGING THE DUTCH HEALTH COUNCIL'S ADVICE

    Nov 1, 2019, 00:00

  • PUK25 THE EFFECTIVENESS OF A DIGITAL PELVIC FLOOR TRAINING PROGRAM IN THE TREATMENT OF URINARY INCONTINENCE - A REAL WORLD EVALUATION

    Nov 1, 2019, 00:00

  • PND10 ANTI-TNF-α INHIBITORS IN PREVENTING ALZHEIMER'S DISEASE (AD): A RETROSPECTIVE REVIEW USING BOTH EMR AND CLAIMS DATA

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMU11 MAIN WEAKNESSES AND PROBLEMATICS OF CYBERSECURITY IN MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PUK33 PATIENT INSIGHTS FOR COMPLEMENT 3 GLOMERULOPATHY (C3G) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • PMD6 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PSS16 ANTI-VEGF INTRAVITREAL INJECTIONS IN PORTUGAL: THE FIRST DECADE 2007-2017

    Nov 1, 2019, 00:00

  • PDB40 PREDICTIVE ANALYSIS OF COST AND CAPACITY EFFECTS OF THE DIGITALIZED SECONDARY CARE SERVICES FOR INSULIN-DEPENDENT DIABETES PATIENTS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • PNS264 AN ASSESSMENT OF THE RECOMMENDATIONS MADE BY NICE'S MEDICAL TECHNOLOGIES EVALUATION PROGRAMME, AND WHETHER THE RECOMMENDATIONS SUPPORT MTEP'S STATED AIMS.

    Nov 1, 2019, 00:00

  • Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study

    Nov 1, 2019, 00:00

  • PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

    Nov 1, 2019, 00:00

  • PCN263 ACCESS TO HEALTH SERVICES FOR PEOPLE WITH CANCER IN PERU: TRENDS IN SOCIO-ECONOMIC INEQUALITIES WITHIN THE FRAMEWORK OF A RESULTS-BASED BUDGETING PROGRAM

    Nov 1, 2019, 00:00

  • Neurological Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PMU10 CONSIDERATIONS FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS) IN VARIANTS OF SPANISH FOR THE UNITED STATES

    Nov 1, 2019, 00:00

  • PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

    Nov 1, 2019, 00:00

  • Mental Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PSU35 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A COMMERCIAL CLAIMS DATABASE STUDY WITH TWO-YEAR FOLLOW-UP

    Nov 1, 2019, 00:00

  • PNS59 INCORPORATING THE PATIENT'S PERSPECTIVE IN ECONOMIC EVALUATIONS OF HEALTHCARE

    Nov 1, 2019, 00:00

  • PMS26 IMPACT OF CHRONIC LOW BACK PAIN ON EMPLOYMENT AND PRODUCTIVITY - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH

    Nov 1, 2019, 00:00

  • PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PBI45 UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

    Nov 1, 2019, 00:00

  • PNS78 RECONCILING ACEA AND MCDA: IS THERE A WAY FORWARD FOR MEASURING COST-EFFECTIVENESS IN THE U.S. HEALTHCARE SETTING?

    Nov 1, 2019, 00:00

  • PBI6 WHAT IS THE APPROPRIATE DISCOUNT RATE IN ECONOMIC EVALUATIONS OF GENE THERAPIES (GT)?

    Nov 1, 2019, 00:00

  • PGI53 A QUALITATIVE STUDY EXPLORING THE BURDEN OF ULCERATIVE COLITIS AMONG CHILD, ADOLESCENT, AND ADULT PATIENTS

    Nov 1, 2019, 00:00

  • PMU142 ASSESSING THE HUMAN AND ECONOMIC BURDEN OF SHORT STATURE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND59 BUDGET IMPACT ANALYSIS OF THE NATIONAL CLINICAL GUIDELINE FOR APPROPRIATE PRESCRIBING OF PSYCHOTROPIC MEDICATION IN PEOPLE WITH DEMENTIA

    Nov 1, 2019, 00:00

  • PNS367 THE NATIONAL HEALTH COUNCIL PATIENT ENGAGEMENT RUBRIC: A GUIDE TO INCORPORATING THE PATIENT VOICE INTO THE HEALTHCARE ECOSYSTEM

    Nov 1, 2019, 00:00

  • PIN107 ASSOCIATION BETWEEN NATURAL COLD REMEDIES AND ANTIBIOTIC THERAPY

    Nov 1, 2019, 00:00

  • PUK2 A SYSTEMATIC REVIEW ASSESSING THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PIN101 ECONOMIC IMPACT OF ICU-ACQUIRED MULTI-DRUG RESISTANT BACTERIAL INFECTIONS: EVIDENCE FROM SOUTHERN EUROPE

    Nov 1, 2019, 00:00

  • PSY3 DISEASE BURDEN OF RHEUMATOID ARTHRITIS IN CHINA

    Nov 1, 2019, 00:00

  • PMH51 BREXANOLONE INJECTION FOR THE TREATMENT OF POSTPARTUM DEPRESSION: MINIMAL IMPORTANT DIFFERENCE AND MEANINGFUL CHANGE

    Nov 1, 2019, 00:00

  • PNS170 CHEAP OR TIMELY DRUG? PRACTICAL IMPACT OF EXTERNAL REFERENCE PRICING POLICY IN THE EUROPEAN UNION

    Nov 1, 2019, 00:00

  • PDG38 RELATIONSHIP BETWEEN RELIGIOSITY-SPIRITUALITY AND MEDICATION ADHERENCE AMONG PATIENTS WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI90 THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES

    Nov 1, 2019, 00:00

  • PSU23 INTRAMEDULLARY NAILING OF FEMORAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE.

    Nov 1, 2019, 00:00

  • PCN25 IMPACT OF GEMTUZUMAB OZOGAMICIN ON THE IRISH HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS

    Nov 1, 2019, 00:00

  • PMH22 PREVALENCE OF DECISION ANALYTICAL MODELLING IN ECONOMIC EVALUATIONS OF MENTAL HEALTH INTERVENTIONS

    Nov 1, 2019, 00:00

  • PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PMD44 PRICING AND REIMBURSEMENT, AND MARKET ACCESS OF THERAPEUTIC MATERIALS (MEDICAL DEVICES/DIAGNOSTICS/BIOMARKERS) IN SOUTH KOREA.

    Nov 1, 2019, 00:00

  • PMH15 BUDGET IMPACT ANALYSIS OF SCHIZOPHRENIA TREATMENT IN INDONESIA

    Nov 1, 2019, 00:00

  • PSU8 COMPARING COSTS OF USING FIBRINOGEN CONCENTRATE VERSUS FRESH FROZEN PLASMA IN THE TREATMENT OF BLEEDING DURING CARDIAC SURGERY IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PSU11 ROBOTIC VS LAPAROSCOPIC RIGHT HEMICOLECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PDB2 USING REAL WORLD DATA TO EXAMINE TRIGLYCERIDES, LDL-CHOLESTEROL, AND HDL-CHOLESTEROL AS PREDICTORS OF PROGRESSION FROM NONALCOHOLIC STEATOHEPATITIS TO HEPATOCELLULAR CANCER AND LIVER CIRRHOSIS

    Nov 1, 2019, 00:00

  • Infectious Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIH39 EVALUATION OF PROPRANOLOL OFF-LABEL USE IN INFANTILE HEMANGIOMA AND EFFECTIVENESS OF RISK MINIMISATION MEASURES TO MITIGATE ADVERSE REACTIONS: A FRENCH AND GERMAN DRUG UTILIZATION STUDY

    Nov 1, 2019, 00:00

  • PDG50 PHARMACEUTICAL PRICING POLICIES IN QATAR AND LEBANON: NARRATIVE REVIEW AND DOCUMENT ANALYSIS

    Nov 1, 2019, 00:00

  • PMH33 COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY

    Nov 1, 2019, 00:00

  • PGI22 HEALTH ECONOMIC EVALUATION OF EARLY LAPAROSCOPIC CHOLECYSTECTOMY FOR THE PATIENT WITH GALLSTONE DISEASE. A MICRO-COSTING ANALYSIS

    Nov 1, 2019, 00:00

  • PMU94 DATA GENERATED BY THE FRENCH COMPASSIONATE USE PROGRAM: HOW CAN THEY CONTRIBUTE TO THE HEALTH TECHNOLOGY ASSESSMENT?

    Nov 1, 2019, 00:00

  • PND33 THE CLINICAL AND ECONOMIC BURDEN OF OBSTRUCTIVE SLEEP APNEA IN ADULTS: A COST-OF-ILLNESS ANALYSIS

    Nov 1, 2019, 00:00

  • PND81 LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE

    Nov 1, 2019, 00:00

  • PIH10 ANALYSING PRESCRIBING PATTERNS AND COSTS OF DRUG TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

    Nov 1, 2019, 00:00

  • PND115 PATIENT REALITIES IN MIGRAINE. LITERATURE REVIEW ENHANCED BY SOCIAL MEDIA

    Nov 1, 2019, 00:00

  • PNS269 PERSPECTIVES ON PRICING AND REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE GREEK HEALTHCARE SETTING: A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • PMU48 PR PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS

    Nov 1, 2019, 00:00

  • PCV74 COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • PNS410 DATA FROM EXPANDED ACCESS PROGRAMS: TREATMENT FIRST, COLLECTION SECOND. AN OVERVIEW OF FDA AND EMA REGULATORY APPROVALS.

    Nov 1, 2019, 00:00

  • PNS158 HEALTH ECONOMIC VALUE OF BLOOD IN SUB-SAHARAN AFRICA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN90 MANAGEMENT AND COST OF FEBRILE NEUTROPENIA (FN) IN THE ONCOLOGY PATIENT

    Nov 1, 2019, 00:00

  • PNS92 PUBLIC AWARENESS OF NURSING REFORM IN THE REPUBLIC OF KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PRS17 COST-EFFECTIVENESS OF A HYPOTHETICAL SCREENING PROGRAM FOR LUNG CANCER AND CARDIOVASCULAR DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • PCN380 A TARGETED REVIEW EVALUATING UNCERTAINTY IN SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS FOR TREATMENTS APPROVED FOR USE SINCE THE INTRODUCTION OF THE 'NEW' CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • PRS4 SABA OVERUSE AND HEALTH CARE RESOURCE UTILIZATION IN A NATIONWIDE SWEDISH ASTHMA COHORT (HERA)

    Nov 1, 2019, 00:00

  • PND93 WHAT GOOD ARE DIGITAL TECHNOLOGIES IN ALZHEIMER'S DISEASE RESEARCH? - A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN279 EFFECT OF THE CHANGE IN COST-EFFECTIVENESS THRESHOLD ON THE NEWLY LISTED ANTICANCER DRUG PRICES IN THE NATIONAL HEALTH INSURANCE OF SOUTH KOREA

    Nov 1, 2019, 00:00

  • PMD51 EVALUATING THE USE AND OUTCOMES OF DIGITALLY ASSISTED VITREO-RETINAL SURGERY: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMD49 MECHANICAL COMPLICATIONS ASSOCIATED WITH INTRAMEDULLARY NAILING FOR TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES

    Nov 1, 2019, 00:00

  • PNS286 SYSTEMATIC REVIEW ON THE ECONOMIC EVALUATION OF THE NON-INVASIVE PRENATAL TESTING

    Nov 1, 2019, 00:00

  • PNS16 IMPROVING ACCESS TIME IN NUCLEAR CARDIOLOGY TOWARDS QUALITY DELIVERY OF HEALTHCARE SERVICES

    Nov 1, 2019, 00:00

  • PIN20 EXPECTED COST-EFFECTIVENESS OF HIGH DOSE VERSUS ADJUVANTED STANDARD DOSE TRIVALENT INFLUENZA VACCINES IN ENGLAND AND WALES: ASSESSMENTS USING DIRECT AND INDIRECT COMPARATIVE EFFECTIVENESS DATA

    Nov 1, 2019, 00:00

  • PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS?

    Nov 1, 2019, 00:00

  • PMS56 CURRENT PATTERNS OF CARE IN THE ASSESSMENT AND TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2019, 00:00

  • CL4 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF THE EFFICACY AND TOLERABILITY OF APALUTAMIDE AND DAROLUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

    Nov 1, 2019, 00:00

  • PNS276 DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?

    Nov 1, 2019, 00:00

  • ND3 SHORT- AND LONG-TERM DISABILITY BURDEN AMONG EMPLOYED PATIENTS RECEIVING DISEASE-MODIFYING TREATMENT FOR MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Economic Evaluation

    Nov 1, 2019, 00:00

  • PND35 CLINICAL AND ECONOMIC BURDEN OF MIGRAINE IN SPAIN, FRANCE, AND THE UNITED KINGDOM: RESULTS OF A POOLED ANALYSIS

    Nov 1, 2019, 00:00

  • PCV88 PHARMACY COLLECTION OF PRESCRIBED SECONDARY PREVENTIVE DRUG THERAPY AFTER MYOCARDIAL INFARCTION - A NORWEGIAN NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS249 HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE AND NORTH AMERICA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDG55 RISK SHARING AGREEMENT ON PRESCRIPTION DRUGS: 5 YEARS EXPERIENCE OF THE KOREA NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN58 FOUR-STATE MARKOV MODEL FOR IMMUNO-ONCOLOGIC THERAPIES

    Nov 1, 2019, 00:00

  • PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY

    Nov 1, 2019, 00:00

  • PMS11 A RETROSPECTIVE COHORT ANALYSIS OF THE BURDEN OF TOTAL KNEE ARTHROPLASTY IN JAPAN

    Nov 1, 2019, 00:00

  • PGI57 NON-BIOLOGIC TREATMENT OF GERMAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF HEALTH CARE RESOURCE USE AND COST ASSOCIATED WITH DISEASE ACTIVITY

    Nov 1, 2019, 00:00

  • PCN4 DINUTUXIMAB BETA WITH ISOTRETINOIN VERSUS ISOTRETINOIN ALONE IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: IMPACT ON LONG-TERM SURVIVAL

    Nov 1, 2019, 00:00

  • SP2 DISCREPANCY IN HEALTH STATE UTILITY VALUES BETWEEN COST-UTILITY ANALYSIS AND REFERENCED ORIGINAL HEALTH UTILITY STUDIES IN CARDIOVASCULAR DISEASE: A REGISTRY-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • Surgery - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PBI91 CHARACTERISTICS AND MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) PATIENTS IN A LARGE REPRESENTATIVE REAL WORLD COHORT

    Nov 1, 2019, 00:00

  • PCV12 ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH HISTORY OF MYOCARDIAL INFARCTION IN FRANCE USING SNDS DATABASE

    Nov 1, 2019, 00:00

  • PND117 PATIENTS' PERSPECTIVES OF LIVING WITH MULTIPLE SCLEROSIS IN GREECE: AN INTERPRETIVE PHENOMENOLOGICAL ANALYSIS

    Nov 1, 2019, 00:00

  • PIN13 FIRST EMA-EUNETHTA PARALLEL CONSULTATION FOR VACCINES

    Nov 1, 2019, 00:00

  • PNS231 MANAGED ENTRY AGREEMENTS FOR PRESCRIPTION DRUGS IN SWEDEN

    Nov 1, 2019, 00:00

  • PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA

    Nov 1, 2019, 00:00

  • PNS93 THE ACTUAL NUTRITIONAL STATUS OF SCHOOLCHILDREN IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PDG89 ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) MARKET ACCESS - A CONTINUING CHALLENGE

    Nov 1, 2019, 00:00

  • PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE

    Nov 1, 2019, 00:00

  • PCN506 MUTATION TESTING AND TREATMENT OF THE MOST COMMON ONCOLOGY DISEASES IN GERMANY: ANALYSIS OF AN ONCOLOGY EMR DATABASE

    Nov 1, 2019, 00:00

  • PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE

    Nov 1, 2019, 00:00

  • PMU111 USE OF EXTERNAL COMPARATORS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS

    Nov 1, 2019, 00:00

  • PND55 ECONOMIC EVALUATION OF ENDOSCOPIC THIRD VENTRICULOSTOMY COMPARED TO SHUNTING IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS IN UZBEKISTAN

    Nov 1, 2019, 00:00

  • PCV56 COST-EFFECTIVENESS OF THE SUSTAINED-RELEASE PACLITAXEL-ELUTING ELUVIA STENT COMPARED TO THE PACLITAXEL-COATED ZILVER PTX STENT FOR ENDOVASCULAR TREATMENT OF PERIPHERAL ARTERY DISEASE: A GERMAN STATUTORY SICKNESS FUND PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PNS209 IMPACT OF GENERICS AND BIOSIMILARS ON BRANDED DRUG LISTING DECISIONS IN SINGAPORE

    Nov 1, 2019, 00:00

  • PNS133 BEYOND INTERNATIONAL PRICING INDEX MODEL IN THE UNITED STATES - IMPACT TO GLOBAL PRICING STRATEGIES ACCESS TO INNOVATIVE MEDICINES

    Nov 1, 2019, 00:00

  • PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00

  • PRS5 TREATMENT PERSISTENCE AND EXACERBATIONS IN PATIENTS WITH ASTHMA INITIATING TREATMENT WITH INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-ADRENERGIC AGONISTS (ICS/LABA): REAL-LIFE STUDY

    Nov 1, 2019, 00:00

  • PCN46 NOVEL APPROACHES TO ADDRESS RESISTANCE TO ANTI PD-1/PD-L1 THERAPY IN NSCLC

    Nov 1, 2019, 00:00

  • PAM4 HEALTHCARE UTILIZATION AND HOSPITALIZATION COSTS AMONG FRAIL AND AT-NUTRITIONAL RISK OR MALNOURISHED OLDER ADULTS

    Nov 1, 2019, 00:00

  • PCV16 MULTIPLE STATISTICAL APPROACHES IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): THE EXAMPLE OF NAXOS, A LARGE FRENCH CER

    Nov 1, 2019, 00:00

  • PNS374 CLINICAL BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN CAREGIVERS OF CANCER PATIENTS: RESULTS FROM LINKING ELECTRONIC HEALTH RECORDS TO PATIENT-REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PGI25 CLINIC AND ECONOMIC ANALYSIS FOR DIAGNISIS AND TREATMENT OF DIFFICULT BILE DUCT STONES WITH SINGEL OPERATOR CHOLANGIISCOPY IN TURKEY

    Nov 1, 2019, 00:00

  • PRO103 THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES

    Nov 1, 2019, 00:00

  • PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PCN331 HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PCN437 RECONSTRUCTION OF INDIVIDUAL PATIENT DATA FROM PUBLISHED SURVIVAL CURVES: CASE OF PRALATREXATE FOR PERIPHERAL T-CELL LYMPHOMAS

    Nov 1, 2019, 00:00

  • PBI84 BASELINE RHEUMATOID ARTHRITIS SEVERITY AMONG PATIENTS RECEIVING BIOLOGIC DMARDS: FINDINGS FROM A REAL-WORLD DATABASE

    Nov 1, 2019, 00:00

  • PCN149 COST-EFFECTIVENESS ANALYSIS OF DABRAFENIB+TRAMETINIB VERSUS WATCHFUL WAITING IN THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED BRAF V600 POSITIVE STAGE III MELANOMA : A FRENCH PERSPECTIVE

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS117 A STUDY ON THE FACTORS AFFECTING CHINESE CITIZENS' WILLINGNESS TO PURCHASE TAX-DEDUCTIBLE PRIVATE HEALTH INSURANCE

    Nov 1, 2019, 00:00

  • PND4 CHARACTERISTICS OF MIGRAINE PATIENTS IN PORTUGUESE HEADACHE SPECIALIST CENTERS

    Nov 1, 2019, 00:00

  • PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK

    Nov 1, 2019, 00:00

  • PCV90 RISK FACTORS, USE OF HEALTH CARE RESOURCES, AND MORTALITY IN PATIENTS WITH MINOR ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK

    Nov 1, 2019, 00:00

  • PRO102 ANALYSIS OF RECENT FRENCH HTA APPRAISALS OF ORPHAN DRUGS WITH OR WITHOUT CONTRIBUTION OF PATIENTS ASSOCIATIONS

    Nov 1, 2019, 00:00

  • PCN417 INFLUENCE 2.0: A TIME-DEPENDENT MODEL TO PREDICT LOCOREGIONAL RECURRENCE AND SECOND PRIMARIES IN EARLY BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?

    Nov 1, 2019, 00:00

  • Injury Trauma - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMS36 BUDGET IMPACT ANALYSIS OF TRIPLE THERAPY AFTER FAILURE OF METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2019, 00:00

  • Injury Public Health

    Nov 1, 2019, 00:00

  • Drugs Generics - Organizational Practices

    Nov 1, 2019, 00:00

  • RARE Information Systems

    Nov 1, 2019, 00:00

  • New Frontiers in Health Technology Assessment Research

    Nov 1, 2019, 00:00

  • PNS366 UNDERSTANDING THE ROLE OF ANCHOR CORRELATIONS IN THE CALCULATION OF MEANINGFUL CHANGE THRESHOLDS FOR HEALTH-RELATED QUALITY OF LIFE RESEARCH

    Nov 1, 2019, 00:00

  • PNS148 VALUE-BASED PROCUREMENT: UNDERSTANDING HOW PAYERS APPROACH AND IMPLEMENT CONTRACTING AND PROCUREMENT OF NOVEL TREATMENTS BASED ON THEIR VALUE

    Nov 1, 2019, 00:00

  • Real World DATA Information Systems

    Nov 1, 2019, 00:00

  • PCV67 BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

    Nov 1, 2019, 00:00

  • PMS33 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PCN371 A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46 (current)
  • 47
  • 48
  • 49
  • 50
  • »